Publications by authors named "Jiejun Du"

Claim this Profile
S
Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years.
Jaya Goswami, Jose F Cardona, Jorge Caso, Denise C Hsu, Alana K Simorellis, Jiejun Du

Clin Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial.
Chong Ma, Jiejun Du, Lan Lan, Archana Kapoor, Gonzalo Perez Marc, Christopher J A Duncan

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years.
Erick F Mayer, Ann R Falsey, Rebecca Clark, Murdo Ferguson, Jose Cardona, Jiejun Du

Clin Infect Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
Jaya Goswami, Jose F Cardona, Denise C Hsu, Alana K Simorellis, Lauren Wilson, Jiejun Du

Lancet Infect Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.
Jaya Goswami, Abdullah H Baqui, Pablo A Doreski, Gonzalo Perez Marc, Gilberto Jimenez, Christopher J A Duncan, Jiejun Du

J Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G Johnson, Jiejun Du

Infect Dis Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G Johnson, Jiejun Du

Infect Dis Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
Eleanor Wilson, Jaya Goswami, Abdullah H Baqui, Pablo A Doreski, Gonzalo Perez-Marc, Christopher J A Duncan, Jiejun Du

N Engl J Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.
Yanfen Guan, Amy Puenpatom, Matthew G Johnson, Ying Zhang, Yujie Zhao, Jiejun Du

Clin Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
Matthew G Johnson, Julie M Strizki, Michelle L Brown, Hong Wan, Hala H Shamsuddin, Jiejun Du

Infection· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis.
Ignacio Martin-Loeches, Andrew F Shorr, Marin H Kollef, Jiejun Du, Maria C Losada

Open Forum Infect Dis· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.
Jason A Roberts, David P Nicolau, Ignacio Martin-Loeches, C Andrew Deryke, Maria C Losada, Jiejun Du

JAC Antimicrob Resist· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Angélica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie, Evgeniy Kovalchuk, Antonio Gonzalez, Jiejun Du

N Engl J Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.
Yoseph Caraco, Gordon E Crofoot, Pablo Andres Moncada, Anna Nikolaevna Galustyan, Dany Badibanga Musungaie, Jiejun Du

NEJM Evid· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Ivan Titov, Richard G Wunderink, Antoine Roquilly, Daniel Rodríguez Gonzalez, Aileen David-Wang, Jiejun Du

Clin Infect Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Johann Motsch, Cláudia Murta de Oliveira, Viktor Stus, Iftihar Köksal, Olexiy Lyulko, Jiejun Du

Clin Infect Dis· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.
Keith S Kaye, Helen W Boucher, Michelle L Brown, Angela Aggrey, Ireen Khan, Jiejun Du

Antimicrob Agents Chemother· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study.
Michelle L Brown, Johann Motsch, Keith S Kaye, Thomas M File, Helen W Boucher, Jiejun Du

Open Forum Infect Dis· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Graham R Foster, Kosh Agarwal, Matthew E Cramp, Sulleman Moreea, Stephen Barclay, Jiejun Du

Hepatology· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Matthew Sims, Valeri Mariyanovski, Patrick McLeroth, Wayne Akers, Yu-Chieh Lee, Jiejun Du

J Antimicrob Chemother· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Size and Shape Analysis of Error-Prone Shape Data.
Jiejun Du, Ian L Dryden, Xianzheng Huang

J Am Stat Assoc· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis